Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| LEGN | PRESS-RELEASE | bullish | 5/10 | Legend Biotech presented five-year follow-up data from CARTITUDE-2 Cohort A at IMS 2026, showing 50% of patients remaine | Sep 25, 2026 |
| ADRX | PRESS-RELEASE | bullish | 7/10 | ADARx Pharmaceuticals priced its upsized IPO of 26.25M shares at $17.00/share, with gross proceeds of ~$446.3M, plus a c | Sep 24, 2026 |
| ALMR | PRESS-RELEASE | bullish | 5/10 | Alamar Biosciences announced a publication in The Lancet Neurology of a longitudinal cohort study using its NULISAseq CN | Sep 24, 2026 |
| NBTX | PRESS-RELEASE | neutral | 4/10 | Nanobiotix reported H1 2026 financial results with a net loss of €34.3M (€0.70 per share) vs €5.4M (€0.11) in H1 2025, d | Sep 24, 2026 |
| RZLT | PRESS-RELEASE | bearish | 6/10 | Rezolute reported Q4 FY2026 EPS of -$0.20, a 42.9% miss vs consensus of -$0.14, with no revenue. The miss was driven by | Sep 24, 2026 |
| REGN | PRESS-RELEASE | neutral | 1/10 | Regeneron Pharmaceuticals, Inc. announced it will report its Q3 2026 results on October 30, 2026. | Sep 24, 2026 |
| PRME | PRESS-RELEASE | bullish | 7/10 | Prime Medicine announced FDA clearance of its IND application for PM647, an in vivo Prime Editor for Alpha-1 Antitrypsin | Sep 24, 2026 |
| CELU | PRESS-RELEASE | mixed | 6/10 | Celularity announced an initial closing of a private placement of senior secured convertible notes and warrants generati | Sep 24, 2026 |
| KALA | PRESS-RELEASE | neutral | 3/10 | Kala Bio announced a non-binding LOI under which a U.S. DNA testing platform would resell Virotek's genomic testing prod | Sep 24, 2026 |
| VTGN | PRESS-RELEASE | neutral | 4/10 | Vistagen presented positive exploratory data at Psych Congress 2026 showing a potential efficacy signal for fasedienol i | Sep 24, 2026 |
| CGEM | PRESS-RELEASE | bullish | 6/10 | Cullinan Therapeutics announced upcoming Q4 2026 pipeline milestones for its T cell engager programs, including multi-do | Sep 24, 2026 |
| MSLE | PRESS-RELEASE | bullish | 6/10 | Satellos received FDA clearance for its IND application for forazapadin in FSHD, a second degenerative muscle disease wi | Sep 24, 2026 |
| LODE | PRESS-RELEASE | neutral | 4/10 | Comstock Inc. announced that its portfolio company Sierra Springs Opportunity Fund (SSOF) has engaged Newmark to advise | Sep 24, 2026 |
| MNOV | PRESS-RELEASE | mixed | 7/10 | MediciNova announced completion of the last patient's final visit in the double-blind portion of its Phase 2b/3 COMBAT-A | Sep 24, 2026 |
| GRML | PRESS-RELEASE | bearish | 6/10 | Greenland Mines Ltd raised over $42 million from existing investors via a registered direct offering of common stock and | Sep 24, 2026 |
| HCM | PRESS-RELEASE | bullish | 7/10 | HUTCHMED announced that two positive Phase III studies of savolitinib plus osimertinib in NSCLC were selected for oral p | Sep 23, 2026 |
| TEVA | PRESS-RELEASE | neutral | 2/10 | Teva published its Q3 2026 Aide Memoire, a compilation of previously disclosed public information, ahead of its Q3 earni | Sep 23, 2026 |
| TEVA | PRESS-RELEASE | neutral | 1/10 | Teva Pharmaceutical Industries Ltd announced it will host a conference call on November 3, 2026 to discuss its Q3 2026 r | Sep 23, 2026 |
| ZYME | PRESS-RELEASE | bullish | 6/10 | Zymeworks completed its acquisition of Theravance Biopharma, adding YUPELRI and TRELEGY royalty streams to its portfolio | Sep 23, 2026 |
| TECH | PRESS-RELEASE | bullish | 6/10 | Bio-Techne shareholders voted to approve the acquisition by Merck KGaA, Darmstadt, Germany. The HSR waiting period has e | Sep 23, 2026 |
| BCDA | PRESS-RELEASE | neutral | 4/10 | BioCardia provided a regulatory milestone update, highlighting a planned Q4 2026 Shonin pre-market submission to Japan's | Sep 23, 2026 |
| SPRC | PRESS-RELEASE | neutral | 3/10 | SciSparc announced that its majority-owned subsidiary NeuroThera, through its collaboration with Clearmind Medicine, has | Sep 23, 2026 |
| GRML | PRESS-RELEASE | neutral | 2/10 | Greenland Mines Ltd. was featured in an editorial by MiningNewsWire discussing rising demand for rare earth and critical | Sep 23, 2026 |
| CMND | PRESS-RELEASE | neutral | 3/10 | Clearmind Medicine announced the U.S. publication of three patent applications covering novel combinations of LSD, ketam | Sep 23, 2026 |
| BMEA | PRESS-RELEASE | bullish | 5/10 | Biomea Fusion terminated its proposed public offering due to unfavorable market conditions, with no securities sold. Thi | Sep 23, 2026 |
| ANIP | PRESS-RELEASE | bullish | 6/10 | ANI Pharmaceuticals received FDA approval for its generic Everolimus Tablets for Oral Suspension (2mg, 3mg, 5mg), a gene | Sep 23, 2026 |
| HELP | PRESS-RELEASE | neutral | 4/10 | Helus Pharma (HELP) reported Q1 2027 EPS of -$0.91, a 3.7% beat vs consensus of -$0.94, on zero revenue. The filing also | Sep 22, 2026 |
| NBTX | PRESS-RELEASE | neutral | 1/10 | Nanobiotix S.A. disclosed its monthly share capital and voting rights as of August 31, 2026, reporting 50,941,528 shares | Sep 22, 2026 |
| BMEA | PRESS-RELEASE | bearish | 5/10 | Biomea Fusion announced an underwritten public offering of common stock and pre-funded warrants, with a 30-day underwrit | Sep 22, 2026 |
| AIM | PRESS-RELEASE | neutral | 3/10 | AIM ImmunoTech CEO issued a letter to shareholders addressing the recent FDA approval of daraxonrasib for pancreatic can | Sep 22, 2026 |